The global burden of lung cancer: current status and future trends A Leiter, RR Veluswamy, JP Wisnivesky Nature reviews Clinical oncology 20 (9), 624-639, 2023 | 552 | 2023 |
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and-negative breast cancer cells by modulating the EGFR/HER-2 pathway NH Thoennissen, J O'kelly, D Lu, GB Iwanski, DT La, S Abbassi, A Leiter, ... Oncogene 29 (2), 285-296, 2010 | 237 | 2010 |
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme D Yin, S Ogawa, N Kawamata, A Leiter, M Ham, D Li, NB Doan, JW Said, ... Oncogene 32 (9), 1155-1163, 2013 | 154 | 2013 |
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ... Prostate cancer and prostatic diseases 18 (2), 122-127, 2015 | 103 | 2015 |
Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis W Chien, J O'Kelly, D Lu, A Leiter, J Sohn, D Yin, B Karlan, J Vadgama, ... International journal of oncology 38 (6), 1741-1747, 2011 | 93 | 2011 |
Clinical trial awareness: Changes over time and sociodemographic disparities A Leiter, MA Diefenbach, J Doucette, WK Oh, MD Galsky Clinical Trials 12 (3), 215-223, 2015 | 84 | 2015 |
Cutaneous papilloma and squamous cell carcinoma therapy utilizing nanosecond pulsed electric fields (nsPEF) D Yin, WG Yang, J Weissberg, CB Goff, W Chen, Y Kuwayama, A Leiter, ... Public Library of Science 7 (8), e43891, 2012 | 54 | 2012 |
Prostatic acid phosphatase is expressed in human prostate cancer bone metastases and promotes osteoblast differentiation A Kirschenbaum, XH Liu, S Yao, A Leiter, AC Levine Annals of the New York Academy of Sciences 1237 (1), 64-70, 2011 | 54 | 2011 |
Use of crowdsourcing for cancer clinical trial development A Leiter, T Sablinski, M Diefenbach, M Foster, A Greenberg, J Holland, ... Journal of the National Cancer Institute 106 (10), dju258, 2014 | 49 | 2014 |
Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines W Chen, A Leiter, D Yin, M Meiring, VJ Louw, HP Koeffler International journal of oncology 37 (3), 737-743, 2010 | 43 | 2010 |
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis S Thapi, A Leiter, M Galsky, EJ Gallagher Journal for ImmunoTherapy of Cancer 7, 1-5, 2019 | 28 | 2019 |
Telemedicine-enabled clinical trial of metformin in patients with prostate cancer MD Galsky, M Shahin, R Jia, DR Shaffer, K Gimpel-Tetra, CK Tsao, ... JCO clinical cancer informatics 1, 1-10, 2017 | 28 | 2017 |
Metabolic effects of JAK1/2 inhibition in patients with myeloproliferative neoplasms M Sapre, D Tremblay, E Wilck, A James, A Leiter, A Coltoff, AG Koshy, ... Scientific Reports 9 (1), 16609, 2019 | 26 | 2019 |
Metabolic disease and adverse events from immune checkpoint inhibitors A Leiter, E Carroll, S De Alwis, D Brooks, J Ben Shimol, E Eisenberg, ... European journal of endocrinology 184 (6), 857-865, 2021 | 23 | 2021 |
The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC. HH Cheng, R Nadal, R Gulati, A Azad, P Twardowski, UN Vaishampayan, ... Journal of Clinical Oncology 32 (4_suppl), 18-18, 2014 | 21 | 2014 |
Assessing the association of diabetes with lung cancer risk A Leiter, A Charokopos, S Bailey, EJ Gallagher, FR Hirsch, D LeRoith, ... Translational Lung Cancer Research 10 (11), 4200, 2021 | 19 | 2021 |
Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes A Leiter, E Carroll, D Brooks, JB Shimol, E Eisenberg, JP Wisnivesky, ... Diabetes research and clinical practice 172, 108633, 2021 | 17 | 2021 |
Obesity and outcomes in patients with metastatic urothelial carcinoma A Leiter, J Doucette, S Krege, CC Lin, N Hahn, T Ecke, G Sonpavde, ... Bladder cancer 2 (3), 341-349, 2016 | 14 | 2016 |
A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8 A Leiter, S Gnjatic, M Fowkes, S Kim-Schulze, I Laface, MD Galsky, ... AACE clinical case reports 6 (4), e151-e160, 2020 | 13 | 2020 |
Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. Q Qin, VG Patel, B Wang, G Mellgard, M Gogerly-Moragoda, X Zhong, ... Journal of Clinical Oncology 38 (15_suppl), e15160-e15160, 2020 | 13 | 2020 |